GlassScriptPhysician profile
Vidhit Puri
NPI 1295153567
$3,804.56
in general payments reported to CMS, 2019-2025
18 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2021: $328 · 2022: $314 · 2023: $199 · 2024: $342 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,894.92 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $420.70 | 2019-2024 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $291.87 | 2021-2025 | Acthar, Terlivaz |
| Amgen INC. | $189.05 | 2021-2025 | Tavneos, Krystexxa |
| Ardelyx, INC. | $163.85 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $129.34 | 2021-2025 | |
| Travere Therapeutics, INC. | $128.85 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $108.54 | 2024-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $96.13 | 2025 | |
| Calliditas Therapeutics US INC. | $71.74 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $66.50 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $65.26 | 2022-2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $41.81 | 2024-2025 | |
| Vifor Pharma, INC. | $37.75 | 2022 | |
| Akebia Therapeutics INC | $32.34 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $23.81 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.45 | 2025 | Jardiance |
| La Jolla Pharmaceutical Company | $18.65 | 2024 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhit Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.